尽管接受了标准心力衰竭治疗,但对于晚期心力衰竭的儿童来说,新的三重组合治疗方法
Isa Ozyilmaz1, Halise Zeynep Genc1, Senay Coban1
1Basaksehir Cam and Sakura City Hospital, Department of Pediatric Cardiology, Istanbul, Turkey.
Cardiology in the young
|September 1, 2025
概括
在晚期心力衰竭的儿童中,三重治疗显著改善了左心室功能. 这种治疗方法解决了内依赖,为儿童心力衰竭治疗提供了有前途的选择.
科学领域:
- 儿童心脏病学
- 心血管研究
- 药理学
背景情况:
- 儿童晚期心力衰竭的单一疗法的有效性有限.
- 关于三重治疗 (莱沃西门丹,达帕格利弗洛辛,萨库比特里尔/ 瓦尔萨坦) 的临床数据不足.
- 需要评估依赖异物治疗的儿童心力衰竭患者的新疗法.
研究的目的:
- 评估三重治疗对晚期心力衰竭儿童左心室功能的影响.
- 确定三重治疗是否可以改善对标准治疗无反应的患者的心脏功能.
- 通过三重疗法评估异能依赖的解决方案.
主要方法:
- 对18名患有晚期心力衰竭的儿科患者进行了回顾性分析.
- 纳入标准:尽管经过了42天的经典心力衰竭治疗,但依赖于异能药物.
- 开始三重治疗 (莱沃西门丹,达帕格利弗洛辛,萨库比特里尔/ 瓦尔萨坦) 并评估心脏参数.
主要成果:
- 观察到左心室喷射率 (2D和辛普森) 的显著改善,以及终端透气和终端静脉直径和体积.
- 左心室全球纵向应变的显著增强 (四腔,三腔和平均值).
- 所有观察到的改善均具有统计学意义 (p < 0. 05).
结论:
- 三重疗法在儿童晚期心力衰竭中显示出改善左心室系统和腹腔功能的潜力.
- 这种疗法可能会导致异能药物依赖的解决.
- 在儿童心力衰竭患者中,三重药物治疗提供了可行的治疗选择.
相关概念视频
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21


